HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  by Aspord, Caroline et al.
HLA-A*0201þ Plasmacytoid Dendritic Cells
Provide a Cell-Based Immunotherapy for
Melanoma Patients
Caroline Aspord1,2,3, Marie-Therese Leccia2,3,4, Dimitri Salameire2,3,5, David Laurin1,2,3,
Laurence Chaperot1,2,3, Julie Charles2,3,4,7 and Joel Plumas1,2,3,6,7
Several sources of evidence suggest that tumor-specific T cells have the potential to control melanoma tumors.
Current active and adoptive therapeutic approaches to elicit such T cells are either not sufficiently clinically
efficient or require fastidious processes that impede their extensive clinical use. As plasmacytoid dendritic cells
(pDCs) have a crucial role in triggering antitumor immunity especially in melanoma, we explored their potential
as a cell-based approach for melanoma immunotherapy. An irradiated human HLA-A*0201þ pDC line loaded
with peptides derived from the major melanoma tumor antigens, MelA/MART-1, gp100/pmel17, tyrosinase, and
MAGE-A3, was used to trigger functional multi-specific T cells ex vivo from peripheral blood mononuclear cells
and tumor-infiltrating lymphocytes from stage I–IV HLA-A*0201þ melanoma patients. pDCs loaded with
melanoma-derived peptides promptly induced high levels of melanoma tumor-specific T cells from both
sources. pDC-primed central/effector memory antitumor T cells were highly functional as indicated by the
specific IFNg secretion and membrane CD107 expression upon stimulation. Cells also exhibited strong
cytotoxicity toward semi-allogeneic melanoma cells and patient-derived tumor cells. The simple design and
potent efficacy of this promising approach provides a preclinical basis for the development of a pDC-based
vaccine and an alternative means to produce tumor-specific T cells for adoptive cellular immunotherapy in
melanoma patients.
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INTRODUCTION
Melanoma represents a major public health issue because of
its growing incidence and the very poor prognosis associated
with metastatic disease. At advanced stages, a very low
response rate to conventional chemotherapy or radiotherapy
treatments is reported (o15%), and alternative therapeutic
options are limited (Sondak and Flaherty, 2011). Immune
modulators, such as IL2 and anti-CTLA4 ipilimumab (Hodi
et al., 2010), slightly improved overall survival. However, this
is only true for a small number of patients, and these therapies
have major side effects (Kirkwood et al., 2008; Lorigan et al.,
2008). New treatment opportunities are presented by the
development of new promising immunotherapies and onco-
gene-targeted therapies (Hocker et al., 2008; Sondak and
Flaherty, 2011; Eggermont and Robert 2012). However,
Vemurafenib, an inhibitor of mutated BRAF (Chapman
et al., 2011), is only effective in about 50% of patients who
display the BRAF-V600E mutation. In addition, it does not
prevent tumor relapse or resistance (Nazarian et al., 2010).
Thus, there is still an unmet need for new strategies able to
widely and efficiently cure melanoma with minimal side
effects (Klein et al., 2011).
Numerous trials based on active or adoptive immuno-
therapies (Rosenberg et al., 2008; Klebanoff et al., 2011;
Palucka et al., 2011) indicate that the immune system has the
potential to control tumors. Indeed, induction or transfer of
functional tumors-specific effector T cells can cause mela-
noma tumors to regress. The efficacy of tumor-specific T cells
in eliminating melanoma cancer cells is further illustrated by
some cases of spontaneous tumor regression, and the
correlation between the density of tumor T-cell infiltrate
and good prognosis (Clemente et al., 1996; Taylor et al.,
2007). Vaccines based on tumor antigen–derived peptides,
allogeneic tumor cell lysates, viral vectors encoding tumor
antigens, or dendritic cells (DCs) loaded with peptides/tumor
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cells have successfully induced cytotoxic T lymphocytes (CTL)
in melanoma patients, but elicited complete response in only
a few cases (Engell-Noerregaard et al., 2009). In contrast,
adoptive transfer of ex vivo–amplified tumor-specific T cells
induced objective tumor regression in 50–72% of patients
(Khammari et al., 2007; Rosenberg et al., 2011). T cells were
amplified from tumor-infiltrating lymphocytes (TILs) extracted
from tumor fragments in the presence of IL2 (Rosenberg et al.,
2008). Elsewhere, clones of known specificity were produced
from peripheral blood mononuclear cells (PBMCs) stimulated
with specific peptide for about 3 months and clonally selected
(Khammari et al., 2009). Current approaches to amplify
tumor-specific T cells require repeated stimulation that may
lead to T-cell exhaustion, are limited to the amplification of
naturally occurring specificities, and are often laborious and
lengthy processes, which impede their broad deployment.
However, the potent clinical efficacy of this approach justifies
the search for alternative ways to easily and promptly produce
tumor-specific T cells with the required qualities for adoptive
transfer.
Plasmacytoid DCs (pDCs), key factors in immunity
(Colonna et al 2004; Lande and Gilliet, 2010), constitute an
emerging potent cell in melanoma. Indeed, pDCs have a
pivotal role in antitumor immunity through their ability to
process and present tumor antigens to T cells (Villadangos
and Young, 2008), and to subsequently induce adaptive
immune responses (Salio et al., 2003). pDCs have been
shown to prime functional responses in vivo, leading to
melanoma tumor regression (Liu et al., 2008). Interestingly,
the potent antitumor effects of applying imiquimod, the Toll-
like receptor 7 ligand (TLR7-L), in melanoma patients
(Steinmann et al., 2000; Zeitouni et al., 2005; Dummer
et al., 2008) may involve pDCs (Palamara et al., 2004;
Dummer et al., 2008). Similarly, the use of CpG (TLR9-L) can
promote tumor regression in mice (Furumoto et al., 2004) and
improve melanoma patients’ response to vaccination (Speiser
et al., 2005) through pDC recruitment and activation
(Pashenkov et al., 2006; Molenkamp et al., 2008). Mobiliza-
tion of pDCs using TLR agonists therefore represents a
promising means to achieve melanoma tumor control.
Despite these outstanding properties, the potential of
pDCs as vectors for cancer immunotherapy has yet to be
exploited. Autologous pDCs are difficult to use owing to their
scarcity and possible functional alteration when harvested
from tumor-bearing patients. A human HLA-A*0201þ pDC
line exists that shares the phenotypic and functional
features of primary pDCs (Chaperot et al., 2006). We availed
ourselves of this to develop a pDC-based strategy to activate
T cells. Our results demonstrated the potential of the
irradiated peptide-pulsed pDCs to promptly trigger highly
functional antitumor (Aspord et al., 2010) and antiviral
(Aspord et al., 2011) immune responses in HLA-A*0201-
matched settings in vitro. Therapeutic efficacy was also
demonstrated, through both an active and adoptive strategy
in vivo in a humanized mouse model bearing melanoma
tumor or virus-infected cells. In this article, we investigated
the pDC line’s capacity to trigger functional multi-specific
T cells ex vivo from PBMCs and TILs from a large series of
melanoma patients after loading with peptides derived from
the four major melanoma tumor antigens, MelA/MART-1,
gp100/pmel17, tyrosinase, and MAGE-A3. The results de-
monstrate the tremendous efficacy of the pDC line to
promptly induce highly functional melanoma-specific T cells.
This promising approach provides a preclinical basis for the
development of a pDC-based vaccine and an efficient
alternative tool to produce tumor-specific T cells for adoptive
cellular immunotherapy for melanoma patients.
RESULTS
HLA-A2-matched allogeneic pDCs effectively induce
antitumor multi-specific CD8þ T cells ex vivo from PBMCs
and TILs from melanoma patients
We investigated the potential of the HLA-A2-matched
peptide-pulsed pDCs to trigger tumor-specific T-cell re-
sponses ex vivo from PBMCs and TILs sampled from stage
I–IV HLA-A*0201þ melanoma patients (Supplementary Table
S1 online). We used HLA-A*0201-restricted immunodomi-
nant peptides derived from four melanoma tumor antigens
(MelA, gp100, tyrosinase, and MAGE-A3), which are widely
expressed in tumors. A massive amplification of tumor-
specific CD8þ T cells was observed for both PBMCs
(Figure 1) and TILs (Figure 2) upon stimulation with pDCs
loaded either with a single peptide (Figures 1a and 2a) or a
mixture of the four peptides (Figures 1b and 2b). This
stimulation was continuously enhanced by serial stimulations
with the peptide-loaded pDCs. Within 20 days, tumor-
specific tetramerþ CD8 T-cell responses reached up to
62.2% for MelA, 41.4% for gp100, 85% for tyrosinase, and
6% for MAGE-A3 (Figures 1c and 2c and Supplementary
Table S2 online). Over the same period (20 days), the
systematic fold increase in absolute tumor-specific T-cell
numbers reached a mean of 6513 (range 113–34249) for
PBMCs and 1184 (range 2–13173) for TILs (Supplementary
Figure S1 online). Importantly, regulatory T cells were not
expanded in this system (Supplementary Figure S2 online).
Thus, HLA-A2-matched allogeneic pDCs elicit strong tumor-
specific CD8þ T-cell responses ex vivo from melanoma
patients’ PBMCs and TILs.
The tumor-specific T cells elicited by the peptide-loaded
pDCs display a central/effector memory phenotype
The stage of differentiation of specific T cells is important for
subsequent therapeutic efficacy; we therefore investigated
the phenotype of the tumor-specific T cells elicited by the
pDC line. We analyzed the naı¨ve (N), central memory (CM),
effector memory (EM), and effector memory CD45RA (EMRA)
populations within tetramerþ CD8 T cells using the CCR7,
CD62L, CD45RA, and CD27 markers (Supplementary Figure
S3 online). The central memory (CD45RAþ CCR7þ ) and
effector memory (CD45RAþ CCR7þ ) subsets predominated
after three stimulations with peptide-loaded pDCs and
represented together 92–99% of tumor-specific T cells.
CD27 and CD62L were expressed by 93 and 24% of
tumor-specific T cells on average, respectively. Thus, the
pDC line elicits CM and EM tumor-specific T cells,
corresponding to fully functional effectors.
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The pDC strategy is efficient with both PBMCs and TILs
regardless of the patients’ clinical stage
The pDC-based strategy induced MelA-, gp100-, tyrosinase-,
and MAGE-A3-specific responses in 100%, 72.5%, 32.3%, and
31.6% of melanoma patients tested, respectively (Figure 3a).
Regardless of the source of the cells, all cultures gave rise to T
cells directed toward at least one antigen. With the aim of
correlating the immune response with disease stage, we defined
a score based on a patient’s ability to respond to one (score 1),
two (score 2), three (score 3), or four (score 4) antigens. Among
c
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Figure 1. The HLA-A*0201þ plasmacytoid dendritic cell (pDC) line loaded with melanoma-derived peptides induces multi-specific T-cell responses
ex vivo from peripheral blood mononuclear cells (PBMCs) from stage I–IV melanoma patients. PBMCs obtained from stage I–IV HLA-A*0201þ melanoma
patients (n¼ 16) were cocultured with irradiated pDCs loaded with (a, c) one or (b, c) a mixture (mix) of peptides from among MelA-, gp100-, tyrosinase-,
and MAGE-A3-derived HLA-A*0201-restricted peptides. Cultures were restimulated weekly in the presence of IL2. T cells were tetramer labeled at days 0, 7, 14,
and 20 of culture to determine the percentage of specific cells. (a, b) Representative dotplots for each tumor antigen (gated on CD8þ T cells). (c) Percentages
of tumor-specific T cells obtained initially and at different culture time points for 16 patients. d, day.
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PBMC samples, 14–34% of patients scored 1–2, whereas
22.5–29% scored 3–4; in contrast, from TIL samples, 30–39%
of patients scored 1–2 and 13.8–15.8% scored 3–4 (Figure 3b).
PBMCs could therefore be a more valuable source of cells for
CTL generation using pDCs. Importantly, a good response could
be elicited even at advanced disease stages, with scores of 3–4
recorded for 43% of stage III and IV patients (Supplementary
Table S1 online). Altogether, these observations demonstrate
that the pDC strategy can be efficient regardless of the type of
sample or clinical stage of the disease.
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Figure 2. The HLA-A*0201þ plasmacytoid dendritic cell (pDC) line loaded with melanoma-derived peptides induces multi-specific T-cell responses
ex vivo from tumor-infiltrating lymphocytes (TILs) from stage III to IV melanoma patients. TILs obtained from stage III to IV HLA-A*0201þ melanoma patients
(n¼17) were cocultured with irradiated pDCs loaded with (a, c) one or (b, c) a mixture (mix) of peptides from among MelA-, gp100-, tyrosinase-, and MAGE-A3-
derived HLA-A*0201-restricted peptides. Cultures were restimulated weekly in the presence of IL2. T cells were tetramer-labeled at days 0, 7, 14, and
20 of culture to determine the percentage of specific cells. (a, b) Representative dotplots for each tumor antigen (gated on CD8þ T cells). (c) Percentages of
tumor-specific T cells at different culture time points for 18 patients. d, day.
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Tumor-specific T cells elicited by HLA-A2-matched allogeneic
pDCs secrete IFNc and express CD107 on the surface upon
restimulation
We further examined the functionality of tumor-specific
CD8þ T cells induced by HLA-A*0201-matched pDCs by
analyzing their effector function. Tumor-specific T cells
elicited in PBMC- or TIL-pDC line cocultures were restimu-
lated with peptide-loaded T2 cells, and tetramerþ CD8þ T
cells were analyzed for IFNg (Figure 4a–d) or CD107 surface
expression (Figure 4e–f). Tumor-specific T cells secreted IFNg
and surface-expressed CD107 upon restimulation with T2
cells loaded with the corresponding, but not a control,
peptide. Importantly, no bystander allogeneic response was
induced, as indicated by the poor activation of nonspecific
tetramerþ -negative CD8þ T cells and CD4þ T cells upon
restimulation (Supplementary Figure S4 online). This suggests
that pDC stimulation elicits functional HLA-A*0201-restricted
tumor-specific T cells without bystander allogeneic responses.
Tumor-specific T cells elicited by HLA-A2-matched allogeneic
pDCs are highly cytotoxic in a HLA- and antigen-restricted
manner
We next tested the cytotoxic potential of the tumor-specific
CD8þ T cells elicited from melanoma patients’ PBMCs
(Figure 5) or TILs (Figure 6) using a standard 51Cr release
assay. T cells elicited from PBMCs stimulated with single- or
multi-peptide-loaded pDCs were able to specifically lyse T2
cells loaded with the corresponding, but not a control,
peptide (Figure 5a and c). They also exhibited strong
cytotoxicity toward HLA-A*0201þ 4Agþ cells (Me275 and
Mel89), but not toward HLA-A*0201þ 4Ag (A375) or HLA-
A*0201 4Agþ (COLO829) allogeneic melanoma tumor
cells (Figure 5b and d). In contrast with unstimulated cells,
TILs were able to lyse peptide-loaded T2 cells after
stimulation with the peptide-loaded pDC line in accordance
with the specific response elicited toward each antigen
(Figure 6a). In addition, T cells were able to lyse allogeneic
melanoma tumor cells in a HLA- and antigen-restricted
manner (Figure 6b and d). They could also lyse autologous
tumor cells, but not the corresponding CD45þ non-tumor
cells (Figure 6c and e), whereas unstimulated TILs could not.
The level of HLA- and antigen-restricted killing of allogeneic
and autologous melanoma tumor cells was significantly
higher for single- and multi-peptide-stimulated TILs com-
pared with unstimulated TILs for all patients (Figure 6f). Thus,
the pDC line elicits fully functional tumor-specific T cells
able to lyse autologous tumors.
DISCUSSION
There is evidence to suggest that tumor-specific T cells have
the potential to control a tumor, particularly in a melanoma
context. Therefore, a potentially promising therapeutic option
is to induce or transfer melanoma-specific T cells. Current
approaches for eliciting such T cells in vivo or ex vivo are
either not clinically efficient or they require fastidious
processes that have impeded their extensive clinical use. As
pDCs have a crucial role in antitumor immunity, we explored
their potential as a cell-based approach for melanoma
immunotherapy. We demonstrate the strong potential of a
pDC-based strategy in inducing multi-specific and highly
functional T-cell responses from both PBMCs and TILs
sampled from melanoma patients. These promising results
provide a preclinical basis for the development of pDC-based
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Figure 3. Melanoma patients’ response to the plasmacytoid dendritic cell
(pDC) strategy and immune score. (a) Percentage of patients responding
to the pDC stimulation for each tumor antigen (16 peripheral blood
mononuclear cell (PBMC), 18 tumor-infiltrating lymphocytes (TIL)). (b) An
immune score was defined based on the patients’ ability to respond to one
(score 1), two (score 2), three (score 3), or four (score 4) antigens. Percentage
of patients for each score, after stimulation with pDCs loaded with either a
single peptide or the four-peptide mixture (16 PBMC, 18 TIL).
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vaccines and an alternative means to produce tumor-specific
T cells for adoptive cellular immunotherapy in melanoma
patients.
The pDC line, once loaded with relevant peptides, can
rapidly induce high levels of tumor-specific T cells from both
PBMCs and TILs from stage I–IV melanoma patients. These
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Figure 4. Tumor-specific T cells primed by peptide-loaded plasmacytoid dendritic cells (pDCs) secrete IFNc and express CD107 on the surface upon specific
restimulation. (a, b) Peripheral blood mononuclear cells (PBMCs) or (c–f) tumor-infiltrating lymphocytes (TILs) were cocultured with irradiated pDCs loaded with
a single peptide or a mixture of the MelA-, GP100-, tyrosinase-, and MAGE-A3-derived HLA-A*0201-restricted peptides and restimulated weekly in the presence
of IL2. Cells were tetramer labeled and restimulated with T2 cells pulsed with a relevant or control peptide. (a–d) IFNg production was assessed by intracellular
staining. CD107 expression was evaluated by adding anti-CD107aþ b antibodies during restimulation. (a, c, e) Representative dotplots gated on
CD8þ T cells (left panels) and tetramerþ CD8þ T cells (right panels). (b, d) Percent IFNgþ tumor-specific T cells. (f) Percent CD107þ tumor-specific T cells.
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T cells display efficient functions. Indeed, amplification rates
for CTL generation reached more than 3.10-fold expansion in
20 days for MelA, starting with PBMC containing o0.03%
specific T cells. These CTLs displayed specific and effective
cytotoxicity toward allogeneic and autologous melanoma
tumor cells. They displayed a central/effector memory
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Figure 5. Tumor-specific T cells elicited by plasmacytoid dendritic cells (pDCs) from melanoma patients’ peripheral blood mononuclear cells (PBMCs) are
highly cytotoxic. T cells induced from melanoma patients’ PBMCs by peptide-loaded pDCs were purified and used as effectors in a 51Cr-release assay.
(a) Representative cytotoxicity assays on peptide-loaded T2 cells upon stimulation with single peptide–loaded pDCs. (b) Representative cytotoxicity assays on allogeneic
melanoma tumor cells upon stimulation with pDCs loaded with MelA (left panel) or the four-peptide mixture (mix; right panel). (c) Killing of peptide-loaded T2 cells
obtained with T cells specific to the corresponding peptide (left, single peptide, n¼23; right, four-peptide mix, n¼ 15). (d) Killing of allogeneic melanoma tumor cells
obtained with PBMCs after stimulation with pDCs loaded with the four-peptide mixture; patients responding to tyrosinase were excluded (n¼ 11).
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phenotype, CD45RA CD62Lþ CD27þ , which would be
optimal for in vivo efficacy and long-term persistence
(Rosenberg et al., 2008). Importantly, CTLs generated using
the pDC line were effective in all patients tested, regardless of
the disease stage and sample source.
The pDC strategy generates potent antitumor cytotoxic T
cells without cross-reactivity to different HLA alleles and
without bystander alloreactivity, as demonstrated by the
antigen- and HLA-A*0201-restricted killing by tumor-specific
CTLs, the incapacity of total T cells from pDC-T cell
cocultures to kill HLA-A*0201-negative tumor cells,
and the absence of activation of nonspecific CD8þ T cells
and CD4þ T cells. A possible explanation for the selective
HLA-restricted responses over allo-responses triggered by
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Figure 6. Tumor-specific T cells elicited by plasmacytoid dendritic cells (pDCs) from melanoma patients’ tumor-infiltrating lymphocytes (TILs) are highly
cytotoxic and lyse autologous melanoma tumor cells. Unstimulated TILs (TIL day (d)0) or T cells induced from TILs by peptide-loaded pDCs were used as
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pDCs could be the differential mobilization of major
histocompatibility complex (MHC)-I and MHC-II molecules
upon stimulation. Indeed, it has been shown that pDCs
are equipped with intracellular stores of MHC-I molecules
ready for rapid mobilization to the surface when an
antigen-specific T-cell response must be initiated (Di Pucchio
et al., 2008). pDCs display low amounts of MHC-II molecules
on their surface and do not upregulate MHC-II synthesis
after activation (Young et al., 2008). Importantly, pDCs can
induce allogeneic T-cell hyporesponsiveness, leading to
prolonged graft survival (Abe et al., 2005). Partial HLA
matching between the stimulating cells and the responding
T cells could explain why weak HLA-restricted tumor-
specific responses were favored over allo-responses (Fabre,
2001), as demonstrated by tumor regression following
allogeneic skin graft in cancer patients (Muir et al., 2006).
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The safety of cell therapies based on allogeneic cells
has already been assessed in clinical trials with melanoma
patients (Duval et al., 2006; Klebanoff et al., 2011; Klein
et al., 2011).
Taken together, these results demonstrate that a strategy
based on an irradiated peptide-loaded pDC line could
overcome the limitations of current T-cell generation proto-
cols with regard to time, complexity, and technical implica-
tions. Indeed, such a strategy could support rapid, large-scale
expansion with a simple procedure. For example, up to
10107 MelA-specific T cells can be generated in 20 days
from only 50 ml blood, using only three simple steps. In
addition, the pDC strategy presented here works well using
PBMCs, which could allow patients to be treated without the
need for tumor samples. The therapy could therefore be
proposed at early stages, before metastases occur, as adjuvant
treatment. Current protocols to produce tumor-specific T cells
for adoptive therapy in melanoma involve fastidious, time-
consuming culture protocols, which have a high dropout rate.
Most of these protocols are based on nonspecific amplifica-
tion of TILs in the presence of IL2, and therefore result in the
generation of T cells with restricted specificities, limited to
those already present and which may be inefficient (Rosen-
berg et al., 2008). Generation of T-cell clones by stimulating
PBMCs with specific peptides takes several months (Kham-
mari et al., 2009) and may lead to T-cell exhaustion. Genetic
engineering of T cells, by transduction with artificial T-cell
receptor (Morgan et al., 2006) or chimeric antigen receptors
(Yun et al., 2000), targets a single antigen and has not been
optimized for clinical efficacy (Hershkovitz et al., 2010).
Importantly, it has been shown that melanoma patients
responding to adoptive cell therapy were treated with TILs
that spend less time in culture, exhibited a more effective lysis
against autologous tumor targets, and were generated from
peripheral lesions rather than invaded lymph nodes (Hersh-
kovitz et al., 2010). The tumor-specific T cells triggered using
our pDC-based strategy, which combines a quick generation,
works with both TILs and PBMCs, and leads to extensive lysis
of autologous tumor cells, should therefore be optimal for
adoptive cell therapy in melanoma patients.
Active DC-based strategies to induce specific T-cell
responses upon vaccination use autologous DCs derived from
CD34þ progenitors or monocytes stimulated by different
cytokine cocktails (Engell-Noerregaard et al., 2009; Palucka
et al., 2010). These time-consuming and expensive ap-
proaches require large volumes of patient blood and must be
performed for each individual, implying interindividual varia-
tions. In contrast, the same pre-validated batches of irradiated
peptide-loaded pDCs could be available immediately for all
HLA-A*0201þ patients. In addition, we have demonstrated
that the pDC strategy elicits more potent responses than mDCs
(Aspord et al., 2010). Thus, our strategy could be used both as
an active and an adoptive cell therapy. A combination
approach might be useful to control tumor outgrowth in the
long term and increase chances of success. In contrast to
current vaccine therapies, which are generally based on a
single antigen, multiple peptides can be loaded onto pDCs.
This broadens the diversity of the immune response, increases
efficient targeting of the tumor, and may help avoid tumor
escape. The modularity of peptide-loaded pDCs allows new
promising specificities to be introduced toward other effective
rejection antigens such as MeloE (Godet et al., 2008), MMP-2
(Godefroy et al., 2005), telomerase (Kyte et al., 2011), or
BRAFV600E, as HLA-A*0201-restricted peptides from the
mutated oncogene have been described (Somasundaram
et al., 2006). As we can induce antitumor immune responses
from ‘‘naı¨ve’’ healthy donors (Aspord et al., 2010), it seems
feasible to elicit responses toward specificities not naturally
developed in patients.
Altogether, these findings provide a preclinical basis for
the use of HLA-matched pDCs as new vectors for melanoma
immunotherapy. The simple design and potent efficacy of the
pDC-based strategy make it very attractive for further clinical
developments, both as a means to easily generate ex vivo
large quantities of specific T cells for adoptive therapy and as
a potent new vector for active immunotherapy.
MATERIALS AND METHODS
Patient samples
Samples were obtained from stage I to IV HLA-A*0201þ melanoma
patients (Supplementary Table S1 online). Approval to conduct the
study was given by the local ethics committee of Grenoble
University Hospital. The Declaration of Helsinki Principles were
followed, and all participants gave their written consent. Blood
samples were obtained from 16 patients, and PBMCs were purified
by Ficoll-Hypaque density gradient centrifugation (Eurobio, Courta-
boeuf, France). Fresh tumor samples were obtained from 13 patients
who underwent surgery for in-transit metastasis. Samples were
mechanically dilacerated and digested in 2 mg ml1 collagenase D
(Roche Diagnostics, Meylan, France) and 20 U ml1 DNase (Sigma,
Saint-Quentine Fallavier, France). Tumor cells were isolated by
adherence, and TILs were enriched from the non-adherent fraction
by density gradient centrifugation where necessary. Pleural effusions
were obtained from four patients with lung metastases and submitted
to density gradient centrifugation to obtain TILs and tumor cells. A
tumor cell line was derived for each patient to provide autologous
tumor cells.
Cell lines
Cultures were performed in RPMI-1640 Glutamax supplemented
with nonessential amino acids, 1 mM sodium pyruvate (Sigma),
20 mg ml1 gentamycin, and 10% FCS (Invitrogen, Paisley, UK).
Melanoma line Me275 was provided by Pr J-C Cerottini (Ludwig
Institute for Cancer Research, Epalinges, Switzerland). Melanoma
lines COLO829 and A375, and T2 and K562 lines were purchased
from ATCC (LGC Standards, Molsheim, France). Melanoma line
Mel89 was generated in our laboratory. The human pDC line
GEN2.2 was cultured as previously described (Chaperot et al.,
2006).
Peptides and tetramers
We used the following tumor-derived HLA-A*0201-restricted pep-
tides (NeoMPS, Strasbourg, France) and the corresponding iTag
HLA-A*0201 tetramers (Beckman Immunomics, Marseille, France):
MelA26–35 (ELAGIGILTV), GP100209–217 (IMDQVPFSV), tyrosi-
nase369–377 (YMDGTMSQV), and MAGE-A3271–279 (FLWGPRALV).
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Induction of antitumor T-cell responses
pDCs were first loaded with the peptide(s) of interest. Briefly, cells
were washed with serum-free RPMI. Thereafter, b2-microglobulin
(0.1 mg ml1; Sigma) and peptide(s) (1–10 mM; NeoMPS) were
added. After 3 hours at 37 1C, peptide-loaded pDCs were washed,
irradiated (30 Gy), and cocultured with HLA-A*0201þ PBMCs or
TILs at a 1:10 ratio in RPMI 10% FCS. Cultures were restimulated
weekly with peptide-loaded pDCs and 200 U ml1 IL2 (Proleu-
kine; Chiron). Specific CD8 T-cell amplification was measured
by tetramer labeling of PBMCs at different time points. To do so,
cells were resuspended in HBSS with 2% FCS, stained with CD45,
iTAg HLA-A*0201 tetramer, and CD3 and CD8 antibodies
(Beckman), and analyzed by flow cytometry using the FACSCa-
libur and CellQuest software (BD, Le Pont de Claix, France). The
differentiation phenotype of tetramerþ T cells was assessed by
labeling with anti-CD45RA, CCR7, CD62L, CD27, CD3, and CD8
antibodies before analysis with the 6-color FACSCanto-II and
DIVA software (BD). FoxP3þCD25þCD4 regulatory T cells
were evaluated using the Human Regulatory T cell Staining kit
(eBiosciences, Paris France).
Functional assays
IFNc secretion and CD107 expression by tetramerþ CD8 T
cells. T cells were first labeled with iTAg HLA-A*0201
tetramer, washed, and restimulated with peptide-pulsed T2
cells (10:1 ratio) for 5.5 hours. For IFNg secretion, 1ml ml1
brefeldinA (BD) was added for the final 3 hours. Cells were
then surface-labeled with anti-CD3 and anti-CD8 anti-
bodies and submitted to IFNg intracellular staining (BD).
For CD107 detection, anti-CD107aþ b antibodies (10 ml
per 1.106 cells; BD) were added to the medium at the start
of restimulation, and Golgi-STOP (0.67 ml ml1) was added
after 1.5 hours. Cells were then labeled with anti-CD3 and
anti-CD8 antibodies.
Cytotoxicity assay. Antigen-specific cytotoxicity was mea-
sured using a standard 51Cr release assay. Effector T cells
were sorted from the coculture using an EasySep human T-
cell enrichment kit (StemCell, Grenoble, France). Target cells
(peptide-pulsed HLA-A*0201þ T2 cells, K562, allogeneic, or
autologous tumor cells) were labeled with 50 mCi 51Cr for
1 hour, before washing and plating with effector T cells at the
indicated E:T ratio in round-bottomed 96-well plates. Plates
were incubated for 4 hours, and radioactivity was measured
in supernatants (30 ml) on a scintillation counter TopCount
NXT (PerkinElmer, Courtaboeuf, France). The mean of
triplicate measurements was expressed as a percentage of
specific lysis using the following formula: 100 (sample
release–spontaneous release)/(maximal release–spontaneous
release).
Statistical analysis. Data were assessed by the Mann–Whitney
nonparametric U-test, Wilcoxon matched paired t-test, and
one-way analysis of variance for statistical significance using
the Prism software (La Jolla, CA).
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